ASMB ASSEMBLY BIOSCIENCES, INC.

BEARISH Impact: 6/10 424B5
Horizon days Filed May 22, 2026 Processed 21d 16h ago SEC 0001193125-26-236812
Notable filing: 424B5
Latest settled — T+5d
ASMB ▼ -6.37% at T+5d
SHORT call ✓ call won +6.37% · α vs SPY +7.45% · entry $28.75 → $26.92
Next anchor: T+20d in 10d
Currently $22.96 · +20.14% from $28.75 entry (call sign-flipped)
Entry anchored
May 22, 03:59 PM ET
via Databento tick
T+1d
-4.21%
call +4.21% · α +4.17%
$27.54
settled 18d ago
T+5d
-6.37%
call +6.37% · α +7.45%
$26.92
settled 12d ago
T+20d
call — · α —
in 10d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Assembly Biosciences (ASMB) filed a preliminary prospectus supplement for an underwritten public offering of common stock and pre-funded warrants under its existing $400M shelf. The offering size and price remain blank (preliminary filing), but the filing confirm dilution to existing holders. Net proceeds are slated for clinical development and general corporate purposes. Gilead Sciences has expressed non-binding interest to participate pro rata.

Actionable Insight

Expect continued near-term pressure as the market absorbs the announced (but not yet priced) equity offering. Watch for the final prospectus supplement with offering size, price, and pricing date; the stock is likely to trade off the reference price of $26.26 until terms are set. Gilead's non-binding interest provides a modest backstop but no floor. Biotech equity offerings typically trade down 3-7% on announcement of a sizable deal; given this is preliminary, the full impact awaits the final pricing.

Key Facts

  • Preliminary prospectus supplement for an underwritten offering of common stock and pre-funded warrants; size and price not yet disclosed.
  • Offering under $400M shelf registration (S-3 filed Mar 19, 2026).
  • Net proceeds to fund clinical development and general corporate purposes.
  • Gilead Sciences indicated non-binding interest to purchase shares pro rata to its ownership percentage.
  • Net tangible book value as of Mar 31, 2026 was $198.6M ($12.50/share) on 15,892,353 shares outstanding.
  • Offering will cause 'immediate and substantial dilution' per the risk factors section.
  • Pre-funded warrants exercisable at $0.001/share, no public trading market expected.
  • Underwriters have a 30-day option to purchase additional shares.
  • 90-day lock-up on the company and directors/officers.
  • Last reported sale price on May 20, 2026 was $26.26 per share.

Financial Impact

Offering size not yet disclosed; based on $26.26 reference price and existing 15.9M shares outstanding, even a modest $50M offering would add ~15-20% dilution. Immediate dilution per share will be substantial (offering price above $12.50 book value).

dilution

Risk Factors

  • Undisclosed offering size could be larger than expected, increasing dilution.
  • Gilead's non-binding indication may not materialize or may be at a discount.
  • No public market for pre-funded warrants, limiting liquidity for those instruments.
  • Current holders face immediate and substantial dilution as stated in the filing.
  • Biotech is pre-revenue, relying on clinical pipeline milestones; capital raises dilute without near-term catalyst.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (10 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-236812
Document: 0001193125-26-236812-index-headers.html0001193125-26-236812
Document: 0001193125-26-236812-index.html0001193125-26-236812
Document: 0001193125-26-236812.txt0001193125-26-236812
8 reports for ASMB
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for ASMB — sortable, filterable
Type Now
Jun 11, 2026
2d ago
Institutional Cluster
NEUTRAL ★ 3/10
$22.22 awaiting T+5awaiting T+5$22.96 (+3.33%)
Jun 5, 2026
7d ago
8-K
NEUTRAL ★ 2/10
$22.89 awaiting T+5awaiting T+5$22.96 (+0.31%)
May 22, 2026
21d ago
424B5
BEARISH ★ 6/10
$28.75 $26.92▲ +6.37%▲ +7.45%$22.96 (+20.14%)
May 22, 2026
22d ago
8-K
NEUTRAL ★ 5/10
$28.34 $26.92▼ −5.01%▼ −6.67%$22.96 (−18.98%)
May 22, 2026
22d ago
Press Release
NEUTRAL ★ 5/10
$28.34 $26.92▼ −5.01%▼ −6.67%$22.96 (−18.98%)
May 7, 2026
5w ago
Press Release
BULLISH ★ 6/10
$29.74 $30.30▲ +1.88%▲ +0.42%$22.96 (−22.80%)
Mar 30, 2026
10w ago
EFFECT
NEUTRAL ★ 3/10
$26.64 $28.53▲ +7.09%▲ +2.79%$22.96 (−13.81%)
Mar 19, 2026
12w ago
Press Release
BULLISH ★ 8/10
$28.46 $27.70▼ −2.67%▼ −0.52%$22.96 (−19.33%)
Showing 8 of 8

US Market Status

Market Closed — Opens Mon (48h 50m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access